Dear Reader,
Don't miss today's Nasdaq standout! GT Biopharma, Inc. (GTBP) is making waves with a remarkable 20% surge.
Why does this matter? Here's a key point: GTBP boasts a low float alert, with approximately 1.16 million shares, as reported by Yahoo Finance.
Given GTBP's float size, it's prone to sudden bouts of volatility, so keep a close eye on
developments.
GT Biopharma, Inc. is a pioneering biopharmaceutical firm dedicated to advancing and commercializing immuno-oncology therapeutic solutions built on the innovative TriKE® NK cell engager platform.
This proprietary platform is engineered to harness and enhance the cancer-fighting capabilities of the body's natural killer cells.
Moreover, GT Biopharma holds an exclusive worldwide license agreement with the University of
Minnesota to further develop and commercialize therapies utilizing TriKE® technology.
Key Technical Analysis - Identifying Potential Catalysts
Following yesterday's close below the $4.00 threshold, GTBP emerged as a potential bounce/healthy reversal candidate.
Today, the excitement continues as GTBP not only breached potential resistance at $4.00 but also surpassed:
- 5-Day Simple Moving Average (SMA)
- 20-Day
SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
Could this signal the start of a support rally to propel GTBP back to prior highs? Keep a close watch on these critical technical levels today.
Catch this Nasdaq breakout opp before it slips away. Stay tuned for rapid updates!
Best regards,
Max Masters
Co-founder, Market Tips Newsletter
